Tax Policy:

Pharmaceutical Industry's Use of the Research Tax Credit

GGD-94-139: Published: May 13, 1994. Publicly Released: Jun 15, 1994.

Additional Materials:


Office of Public Affairs
(202) 512-4800

Pursuant to a congressional request, GAO reviewed the major tax benefits used by the pharmaceutical industry, focusing on: (1) the characteristics of the companies claiming research tax credits; and (2) whether Internal Revenue Service (IRS) tax administration efforts adequately ensure that pharmaceutical companies comply with tax credit legislation.

GAO found that: (1) between 1981 and 1990, the pharmaceutical industry's share of research tax credits increased by 12 percent and totalled $1.24 billion; (2) large pharmaceutical companies with assets of $250 million or more are the primary beneficiaries of research tax credits; (3) although small biotechnology companies invest more of their resources in research and development than large companies, they do not have sufficient tax liabilities to benefit from the tax credit; (4) the research tax credit is difficult for IRS to administer because auditors cannot adequately distinguish research stages, audit issues are often highly technical, and proposed regulations are confusing; and (5) although Treasury plans to clarify and finalize tax credit regulations, the regulations are not expected to distinguish between research for product innovation and research for product development.

Jan 14, 2021

Nov 18, 2020

Nov 9, 2020

Oct 19, 2020

Sep 23, 2020

Aug 31, 2020

Jun 29, 2020

Jun 16, 2020

May 1, 2020

Apr 30, 2020

  • tax icon, source: Eyewire

    Priority Open Recommendations:

    Internal Revenue Service
    GAO-20-548PR: Published: Apr 23, 2020. Publicly Released: Apr 30, 2020.

Looking for more? Browse all our products here